Allianz Asset Management AG reduced its position in Iradimed Corp (NASDAQ:IRMD) by 19.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,211 shares of the medical equipment provider’s stock after selling 11,177 shares during the period. Allianz Asset Management AG owned approximately 0.42% of Iradimed Corp worth $502,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in IRMD. Skylands Capital LLC purchased a new stake in shares of Iradimed Corp during the third quarter worth about $251,000. First Quadrant L P CA purchased a new stake in shares of Iradimed Corp during the third quarter worth about $242,000. Mondrian Investment Partners LTD increased its stake in shares of Iradimed Corp by 73.0% in the third quarter. Mondrian Investment Partners LTD now owns 135,729 shares of the medical equipment provider’s stock worth $2,306,000 after buying an additional 57,272 shares during the last quarter. Wasatch Advisors Inc. increased its stake in shares of Iradimed Corp by 15.5% in the third quarter. Wasatch Advisors Inc. now owns 97,000 shares of the medical equipment provider’s stock worth $1,648,000 after buying an additional 13,000 shares during the last quarter. Finally, Spark Investment Management LLC increased its stake in shares of Iradimed Corp by 102.9% in the third quarter. Spark Investment Management LLC now owns 71,000 shares of the medical equipment provider’s stock worth $1,206,000 after buying an additional 36,000 shares during the last quarter. 22.86% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Iradimed Corp (NASDAQ:IRMD) traded up 0.57% during midday trading on Friday, reaching $8.80. 33,295 shares of the company were exchanged. The stock has a market capitalization of $94.50 million, a P/E ratio of 14.67 and a beta of 1.66. Iradimed Corp has a 12-month low of $7.85 and a 12-month high of $22.53. The company has a 50 day moving average price of $8.43 and a 200-day moving average price of $9.86.
Iradimed Corp (NASDAQ:IRMD) last posted its earnings results on Monday, February 6th. The medical equipment provider reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.07. Iradimed Corp had a return on equity of 24.50% and a net margin of 22.20%. The company had revenue of $6 million for the quarter, compared to the consensus estimate of $6.09 million. During the same quarter in the previous year, the business earned $0.19 earnings per share. The company’s revenue for the quarter was down 31.9% on a year-over-year basis. On average, analysts forecast that Iradimed Corp will post $0.16 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Iradimed Corp (IRMD) Shares Sold by Allianz Asset Management AG” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://sportsperspectives.com/2017/04/21/allianz-asset-management-ag-sells-11177-shares-of-iradimed-corp-irmd-updated-updated.html.
IRMD has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Iradimed Corp from a “buy” rating to a “hold” rating in a report on Monday, January 2nd. TheStreet downgraded shares of Iradimed Corp from a “c-” rating to a “d+” rating in a research note on Monday, January 23rd.
In other news, CEO Roger E. Susi acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 9th. The shares were purchased at an average price of $8.60 per share, for a total transaction of $86,000.00. Following the acquisition, the chief executive officer now owns 15,000 shares of the company’s stock, valued at $129,000. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 69.00% of the stock is currently owned by insiders.
Iradimed Corp Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed Corp and related companies with MarketBeat.com's FREE daily email newsletter.